A Phase 1/2 interventional study of AZD5363 when combined with weekly paclitaxel. and AZD5363 when combined with weekly paclitaxel. in Advanced or Metastatic Breast Cancer and ER+ve Advanced or Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 41 sites in 11 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 63rd largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2012, is one of 12 in phase 1/2, and was the 100th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in Oman, Qatar, Saudi Arabia and 1 more country
Ages 18+ · Women only
AstraZeneca · Sites in United States, France, Germany and 6 more countries
Ages 18–130
AstraZeneca · Sites in Kazakhstan
Ages 18–99
AstraZeneca · Sites in United States, United Kingdom
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 43 · Phase 3 46 · Phase 4 7
First in 1996; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 148 across the 125 interventional studies, 508 across the 72 observational. Of the 144 that completed or were terminated, 32 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
16 of the studies in Breast Neoplasms by AstraZeneca that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT05629585Phase 3AstraZenecaA Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | 2027-09-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 198 studies in Breast Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety and efficacy of different doses and schedules of AZD5363, when in combination with paclitaxel, in treatment of patients with advanced or metastatic breast cancer. Also to investigate a selected dose and schedule of AZD5363 in combination with paclitaxel vs. paclitaxel in combination with placebo in treatment of patients with estrogen receptor-positive advanced or metastatic breast cancer, including a subgroup who have the phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) tumour mutation.
This is a Phase I/II multicentre, study investigating the safety, tolerability and efficacy of a twice-daily oral formulation of AZD5363 when combined with a weekly intravenous paclitaxel infusion in patients with advanced or metastatic breast cancer. Study treatment is given in 28-day cycles, comprising three weeks on-therapy followed by one week off-therapy.
The study will be conducted in two parts:
Part A. Approximately 40 patients will be recruited to this Phase I multiple ascending-dose safety run-in evaluation of each of two intermittent dosing schedules (2 days per week or 4 days per week) of AZD5363 given in combination with weekly paclitaxel. The study population is female patients, 18 years or older, with advanced or metastatic breast cancer.
The purpose of Part A is to assess the comparative safety, tolerability, pharmacokinetics and preliminary efficacy of both schedules to determine one dose and schedule of AZD5363 to take forward to study Part B in combination with weekly paclitaxel.
Part A assessments will be made in dose-escalating cohorts of 3 to 6 patients to determine a recommended dose in each of the schedules. A total of 6 patients must be evaluated at a selected dose level for it to be confirmed as the recommended dose. All dose evaluations and recommendations will be conducted by a Safety Review Committee.
Part A Patients will undergo assessments up to to withdrawal from the study or to discontinuation of study therapy.
Part B. A minimum of 100 patients will be recruited to this Phase II double-blind, placebo-controlled, stratified and randomised evaluation of two treatment regimens: AZD5363 (at a dose selected and schedule from Part A) in combination with weekly paclitaxel vs. weekly paclitaxel plus placebo. The study population is female patients with Estrogen Receptor Positive advanced or metastatic breast cancer; of which approximately 50 will have the phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) mutation.
Part B patients will be stratified by PIK3CA tumour mutation status as: tumour mutation positive or tumour mutation not-detected. Under each stratum patients will be randomised to receive either paclitaxel + AZD5363 or paclitaxel + placebo.
The purpose of Part B is to assess relative efficacy of both active and placebo regimens by comparison of: progression-free survival, overall survival, tumour response, safety and tolerability in the overall ER+ve advanced or metastatic breast cancer population, and in a subgroup of these patients with the PIK3CA tumour mutation. Patient safety and therapy tolerability will be monitored by an independent Safety Review Committee throuighout the course of Part B.
Part B patients will be followed for assessment of overall survival, or to withdrawal from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Part B: any prior chemotherapy for advanced or metastatic breast cancer.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
See intervention description below.
Drug: AZD5363 when combined with weekly paclitaxel.
See intervention description below.
Drug: AZD5363 when combined with weekly paclitaxel.
See intervention description below.
Drug: AZD5363when combined with weekly paclitaxel.
See intervention description below.
Drug: A placebo in combination with weekly paclitaxel.
AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Dose-limiting Toxicity (DLT) Events - Part A
An Adverse Event (AE) or laboratory abnormality considered to be related to study drug, that starts at any time during the DLT evaluation period (Cycle 1) and is dose limiting
Time frame: During Part A DLT evaluation period (Cycle 1, up to 28 days)
Progression Free Survival (PFS) - Part B
Time from randomisation to date of objective disease progression or death (by any cause in the absence of progression). Progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \>= 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on the study, and an absolute increase of \>=5mm, or progression of non-target lesions or the appearance of new lesions.
Time frame: From randomisation date to date of objective disease progression or death (by any cause) whichever came first, assessed every 12 wks (median total treatment duration AZD5363=325.5 days; Placebo=245 days)
Change in Tumour Size at 12 Weeks
Percentage change from baseline to week 12 in sum of longest diameters of target lesions as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1). Based on patients with measurable disease who had sufficient data available to either calculate or impute a change at 12 weeks
Time frame: RECIST tumour assessments every 12 weeks
Objective Response Rate (ORR) at Week 12
Percentage of patients who have at least one visit response of Complete Response or Partial Response prior to any evidence of progression at week 12 as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm; Objective Response Rate (ORR) = CR + PR
Time frame: RECIST tumour assessments every 12 weeks
Best Objective Response (BOR)
Number of patients, taking their BOR, which is their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.
Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Overall Objective Response Rate
Percentage of patients, taking their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm. Overall Response Rate (ORR) = CR + PR
Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Number of Subjects Without Progression Disease at Week 12 - Part A
Percentage of patients with a 12 week visit response of CR, PR or SD (as defined by RECIST 1.1) with no evidence of previous progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.
Time frame: up to 12 weeks
Duration of Response (DOR) - Part B
Date of first documentation of response (Complete Response/Partial Response) until the date of disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.. If a subject does not progress following a response, then their DOR will use the PFS censoring time.
Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Durable Response Rate (DRR) - Part B
Percentage of patients who have a Complete Response (CR) or Partial Response (PR) lasting continuously for at least 24 weeks as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: PR, \>=30% decrease in the sum of the longest diameter of target lesions; CR, disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.
Time frame: From date of randomisation, assessed every 12 weeks (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
Overall Survival - Part B
The interval between the date of randomisation and the date of patient death due to any cause. All Part B patients were analysed, number of deaths is presented.
Time frame: From date of randomisation, assessed every 12 weeks, up until the time of final statistical analysis. (median total treatment duration AZD5363 = 325.5 days; Placebo = 245 days).
| Milestone | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Started | 12 | 8 | 5 | 7 | 6 | 54 | 56 |
| Received azd5363/placebo treatment | 12 | 8 | 5 | 7 | 6 | 54 | 55 |
| Did not receive azd5363/placebo trt | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Completed | 6 | 4 | 0 | 0 | 0 | 40 | 37 |
| Not completed | 6 | 4 | 5 | 7 | 6 | 14 | 19 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 1 | 0 | 11 | 16 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Any reason not specifically recorded | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 6 | 3 | 4 | 5 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
An Adverse Event (AE) or laboratory abnormality considered to be related to study drug, that starts at any time during the DLT evaluation period (Cycle 1) and is dose limiting
| participants | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Dose-limiting Toxicity (DLT) Events - Part A | 0 | 2 | 0 | 0 | 2 | — | — |
Time from randomisation to date of objective disease progression or death (by any cause in the absence of progression). Progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \>= 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on the study, and an absolute increase of \>=5mm, or progression of non-target lesions or the appearance of new lesions.
| Months | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) - Part B | — | — | — | — | — | 10.9 (8.3 to 12.4) | 8.4 (8.2 to 10.8) |
Percentage change from baseline to week 12 in sum of longest diameters of target lesions as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1). Based on patients with measurable disease who had sufficient data available to either calculate or impute a change at 12 weeks
| % change from baseline | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Change in Tumour Size at 12 Weeks | -11.0 ± 33.42 | -15.7 ± 13.33 | -19.1 ± 17.73 | -18.3 ± 37.74 | -10.2 ± 24.84 | -34.2 ± 28.91 | -25.4 ± 35.87 |
Percentage of patients who have at least one visit response of Complete Response or Partial Response prior to any evidence of progression at week 12 as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm; Objective Response Rate (ORR) = CR + PR
| % of participants | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) at Week 12 | 41.7 | 12.5 | 0 | 0 | 0 | 50 | 42.9 |
Number of patients, taking their BOR, which is their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.
| Participants | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| Partial Response (PR) | 0 | 2 | 1 | 1 | 0 | 29 | 28 |
| Stable Disease (SD) | 7 | 4 | 3 | 4 | 3 | 14 | 14 |
| Progression | 4 | 1 | 1 | 1 | 2 | 6 | 8 |
| Not Evaluable (NE) | 1 | 1 | 0 | 1 | 1 | 2 | 2 |
Percentage of patients, taking their best objective tumour response based on RECIST measurements throughout the whole study as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm. Overall Response Rate (ORR) = CR + PR
| % of participants | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Overall Objective Response Rate | 0 | 25 | 20 | 14.3 | 0 | 59.3 | 57.1 |
Percentage of patients with a 12 week visit response of CR, PR or SD (as defined by RECIST 1.1) with no evidence of previous progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.
| Participants | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Number of Subjects Without Progression Disease at Week 12 - Part A | 6 | 5 | 3 | 4 | 2 | — | — |
Date of first documentation of response (Complete Response/Partial Response) until the date of disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.. If a subject does not progress following a response, then their DOR will use the PFS censoring time.
| Months | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) - Part B | — | — | — | — | — | 8.3 (6 to 11.3) | 8.2 (5.6 to 10.6) |
Percentage of patients who have a Complete Response (CR) or Partial Response (PR) lasting continuously for at least 24 weeks as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: PR, \>=30% decrease in the sum of the longest diameter of target lesions; CR, disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm.
| % of participants | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Durable Response Rate (DRR) - Part B | — | — | — | — | — | 48.1 | 37.5 |
The interval between the date of randomisation and the date of patient death due to any cause. All Part B patients were analysed, number of deaths is presented.
| months | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Overall Survival - Part B | — | — | — | — | — | 32.8 (21.3 to 32.8) | NA (20.9 to NA) |
Collected over Time of signature of informed consent throughout the treatment period up to and including the follow-up period (median follow-up AZD5363 16.9 months; Placebo 15.2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Schedule 1 560 mg bd | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Sched 1 - AZD5363 640 mg bd | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| Sched 2 - AZD5363 360 mg bd | 1/5 (20%) | 0/5 (0%) | 5/5 (100%) |
| Sched 2 - AZD5363 400 mg bd | 1/7 (14.3%) | 1/7 (14.3%) | 7/7 (100%) |
| Part A Schedule 2 480 mg bd | 0/6 (0%) | 4/6 (66.7%) | 6/6 (100%) |
| Part B AZD5363 | 13/54 (24.1%) | 13/54 (24.1%) | 50/54 (92.6%) |
| Part B Placebo | 15/56 (26.8%) | 8/55 (14.5%) | 48/55 (87.3%) |
| Event | Part A Schedule 1 560 mg bd | Sched 1 - AZD5363 640 mg bd | Sched 2 - AZD5363 360 mg bd | Sched 2 - AZD5363 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/12 | 0/8 | 0/5 | 1/7 | 1/6 | 0/54 | 0/55 |
| Drug hypersensitivityImmune system disorders | 0/12 | 0/8 | 0/5 | 0/7 | 1/6 | 0/54 | 0/55 |
| Lower respiratory tract infection bacterialInfections and infestations | 0/12 | 0/8 | 0/5 | 0/7 | 1/6 | 0/54 | 0/55 |
| PneumoniaInfections and infestations | 0/12 | 0/8 | 0/5 | 0/7 | 1/6 | 0/54 | 0/55 |
| Urinary tract infectionInfections and infestations | 0/12 | 0/8 | 0/5 | 0/7 | 1/6 | 0/54 | 0/55 |
| Renal failureRenal and urinary disorders | 0/12 | 0/8 | 0/5 | 0/7 | 1/6 | 0/54 | 0/55 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 0/8 | 0/5 | 1/7 | 0/6 | 0/54 | 0/55 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/12 | 0/8 | 0/5 | 1/7 | 0/6 | 0/54 | 0/55 |
| NeutropeniaBlood and lymphatic system disorders | 0/12 | 0/8 | 0/5 | 1/7 | 0/6 | 0/54 | 0/55 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/8 | 0/5 | 1/7 | 0/6 | 0/54 | 0/55 |
| Event | Part A Schedule 1 560 mg bd | Sched 1 - AZD5363 640 mg bd | Sched 2 - AZD5363 360 mg bd | Sched 2 - AZD5363 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/8 | 5/5 | 6/7 | 6/6 | 0/54 | 0/55 |
| DiarrhoeaGastrointestinal disorders | 11/12 | 7/8 | 0/5 | 0/7 | 0/6 | 0/54 | 0/55 |
| AstheniaGeneral disorders | 0/12 | 0/8 | 1/5 | 6/7 | 3/6 | 0/54 | 0/55 |
| NauseaGastrointestinal disorders | 0/12 | 0/8 | 3/5 | 2/7 | 5/6 | 0/54 | 0/55 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/8 | 0/5 | 0/7 | 0/6 | 41/54 | 15/55 |
| VomitingGastrointestinal disorders | 0/12 | 0/8 | 2/5 | 2/7 | 4/6 | 0/54 | 0/55 |
| NauseaGastrointestinal disorders | 8/12 | 5/8 | 0/5 | 0/7 | 0/6 | 0/54 | 0/55 |
| AstheniaGeneral disorders | 6/12 | 5/8 | 0/5 | 0/7 | 0/6 | 0/54 | 0/55 |
| DizzinessNervous system disorders | 3/12 | 5/8 | 0/5 | 0/7 | 2/6 | 0/54 | 0/55 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 0/8 | 3/5 | 0/7 | 1/6 | 0/54 | 0/55 |
All patients with data who were included in the full analysis set for Part A and the intention to treat analysis set in Part B'
| Age, Continuous(Years) | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 52.2 ± 9.92 | 58.8 ± 12.78 | 56.6 ± 10.26 | 47.1 ± 9.41 | 49.8 ± 13.12 | 54.3 ± 10.01 | 57.4 ± 11.38 | 58.8 ± 11.24 |
| Age, Customized(Participants) | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| <50 | 5 | 3 | 1 | 4 | 2 | 19 | 16 | 50 |
| >=50 - <65 | 5 | 2 | 3 | 3 | 3 | 24 | 26 | 66 |
| >=65 | 2 | 3 | 1 | 0 | 1 | 11 | 14 | 32 |
| Sex: Female, Male(Participants) | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 12 | 8 | 5 | 7 | 6 | 54 | 56 | 148 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A Schedule 1 560 mg bd | Part A Schedule 1 640 mg bd | Part A Schedule 2 360 mg bd | Part A Schedule 2 400 mg bd | Part A Schedule 2 480 mg bd | Part B AZD5363 | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 0 | 0 | 12 | 15 | 28 |
| Black Or African American | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 10 | 8 | 5 | 7 | 6 | 24 | 18 | 78 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 15 | 16 | 31 |
| Other | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2012 to primary completion in Jan 2017, 51 months.
Results were first posted in Apr 2019, 2 years 2 months after primary completion.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 51 months is below that.
Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.